Literature DB >> 33832487

A review of prospective pathways and impacts of COVID-19 on the accessibility, safety, quality, and affordability of essential medicines and vaccines for universal health coverage in Africa.

Floriano Amimo1,2, Ben Lambert3, Anthony Magit4, Masahiro Hashizume5.   

Abstract

BACKGROUND: The ongoing pandemic of coronavirus disease 2019 (COVID-19) has the potential to reverse progress towards global targets. This study examines the risks that the COVID-19 pandemic poses to equitable access to essential medicines and vaccines (EMV) for universal health coverage in Africa.
METHODS: We searched medical databases and grey literature up to 2 October 2020 for studies reporting data on prospective pathways and innovative strategies relevant for the assessment and management of the emerging risks in accessibility, safety, quality, and affordability of EMV in the context of the COVID-19 pandemic. We used the resulting pool of evidence to support our analysis and to draw policy recommendations to mitigate the emerging risks and improve preparedness for future crises.
RESULTS: Of the 310 records screened, 134 were included in the analysis. We found that the disruption of the international system affects more immediately the capability of low- and middle-income countries to acquire the basket of EMV. The COVID-19 pandemic may facilitate dishonesty and fraud, increasing the propensity of patients to take substandard and falsified drugs. Strategic regional cooperation in the form of joint tenders and contract awarding, joint price negotiation and supplier selection, as well as joint market research, monitoring, and evaluation could improve the supply, affordability, quality, and safety of EMV. Sustainable health financing along with international technology transfer and substantial investment in research and development are needed to minimize the vulnerability of African countries arising from their dependence on imported EMV. To ensure equitable access, community-based strategies such as mobile clinics as well as fees exemptions for vulnerable and under-served segments of society might need to be considered. Strategies such as task delegation and telephone triage could help reduce physician workload. This coupled with payments of risk allowance to frontline healthcare workers and health-literate healthcare organization might improve the appropriate use of EMV.
CONCLUSIONS: Innovative and sustainable strategies informed by comparative risk assessment are increasingly needed to ensure that local economic, social, demographic, and epidemiological risks and potentials are accounted for in the national COVID-19 responses.

Entities:  

Keywords:  Africa; COVID-19; Essential medicines; Health policy; Health systems; SARS-CoV-2; Universal health coverage; Vaccines

Year:  2021        PMID: 33832487     DOI: 10.1186/s12992-021-00666-8

Source DB:  PubMed          Journal:  Global Health        ISSN: 1744-8603            Impact factor:   4.185


  55 in total

1.  Measles: Democratic Republic of the Congo recorded over 6000 deaths last year.

Authors:  Elisabeth Mahase
Journal:  BMJ       Date:  2020-01-08

2.  DRC faces new Ebola outbreak, covid-19, and measles all at once.

Authors:  Owen Dyer
Journal:  BMJ       Date:  2020-06-04

3.  Start as we mean to go on.

Authors: 
Journal:  Lancet Microbe       Date:  2020-05-11

Review 4.  Essential medicines for universal health coverage.

Authors:  Veronika J Wirtz; Hans V Hogerzeil; Andrew L Gray; Maryam Bigdeli; Cornelis P de Joncheere; Margaret A Ewen; Martha Gyansa-Lutterodt; Sun Jing; Vera L Luiza; Regina M Mbindyo; Helene Möller; Corrina Moucheraud; Bernard Pécoul; Lembit Rägo; Arash Rashidian; Dennis Ross-Degnan; Peter N Stephens; Yot Teerawattananon; Ellen F M 't Hoen; Anita K Wagner; Prashant Yadav; Michael R Reich
Journal:  Lancet       Date:  2016-11-08       Impact factor: 79.321

5.  The potential public health consequences of COVID-19 on malaria in Africa.

Authors:  Ellie Sherrard-Smith; Alexandra B Hogan; Arran Hamlet; Oliver J Watson; Charlie Whittaker; Peter Winskill; Fatima Ali; Audu B Mohammad; Perpetua Uhomoibhi; Ibrahim Maikore; Nnenna Ogbulafor; Jamilu Nikau; Mara D Kont; Joseph D Challenger; Robert Verity; Ben Lambert; Matthew Cairns; Bhargavi Rao; Marc Baguelin; Lilith K Whittles; John A Lees; Sangeeta Bhatia; Edward S Knock; Lucy Okell; Hannah C Slater; Azra C Ghani; Patrick G T Walker; Okefu Oyale Okoko; Thomas S Churcher
Journal:  Nat Med       Date:  2020-08-07       Impact factor: 87.241

6.  Routine childhood immunisation during the COVID-19 pandemic in Africa: a benefit-risk analysis of health benefits versus excess risk of SARS-CoV-2 infection.

Authors:  Kaja Abbas; Simon R Procter; Kevin van Zandvoort; Andrew Clark; Sebastian Funk; Tewodaj Mengistu; Dan Hogan; Emily Dansereau; Mark Jit; Stefan Flasche
Journal:  Lancet Glob Health       Date:  2020-07-17       Impact factor: 26.763

7.  What does the COVID-19 pandemic mean for HIV, tuberculosis, and malaria control?

Authors:  Floriano Amimo; Ben Lambert; Anthony Magit
Journal:  Trop Med Health       Date:  2020-05-13

8.  HIV-related travel restrictions: trends and country characteristics.

Authors:  Felicia Chang; Helen Prytherch; Robin C Nesbitt; Annelies Wilder-Smith
Journal:  Glob Health Action       Date:  2013-06-03       Impact factor: 2.640

9.  Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models.

Authors:  Britta L Jewell; Edinah Mudimu; John Stover; Debra Ten Brink; Andrew N Phillips; Jennifer A Smith; Rowan Martin-Hughes; Yu Teng; Robert Glaubius; Severin Guy Mahiane; Loveleen Bansi-Matharu; Isaac Taramusi; Newton Chagoma; Michelle Morrison; Meg Doherty; Kimberly Marsh; Anna Bershteyn; Timothy B Hallett; Sherrie L Kelly
Journal:  Lancet HIV       Date:  2020-08-06       Impact factor: 12.767

10.  Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis.

Authors:  Daniel J Weiss; Amelia Bertozzi-Villa; Susan F Rumisha; Punam Amratia; Rohan Arambepola; Katherine E Battle; Ewan Cameron; Elisabeth Chestnutt; Harry S Gibson; Joseph Harris; Suzanne Keddie; Justin J Millar; Jennifer Rozier; Tasmin L Symons; Camilo Vargas-Ruiz; Simon I Hay; David L Smith; Pedro L Alonso; Abdisalan M Noor; Samir Bhatt; Peter W Gething
Journal:  Lancet Infect Dis       Date:  2020-09-21       Impact factor: 25.071

View more
  4 in total

1.  Safety and Adverse Events Related to COVID-19 mRNA Vaccines; a Systematic Review.

Authors:  SeyedAhmad SeyedAlinaghi; Amirali Karimi; Zahra Pashaei; Arian Afzalian; Pegah Mirzapour; Kobra Ghorbanzadeh; Afsaneh Ghasemzadeh; Mohsen Dashti; Newsha Nazarian; Farzin Vahedi; Marcarious M Tantuoyir; Ahmadreza Shamsabadi; Omid Dadras; Esmaeil Mehraeen
Journal:  Arch Acad Emerg Med       Date:  2022-05-22

2.  The implications of globalization on COVID-19 vaccination in Europe.

Authors:  Dan Lupu; Ramona Tiganasu
Journal:  Sci Rep       Date:  2022-10-19       Impact factor: 4.996

Review 3.  Addressing Inequalities Toward Inclusive Governance for Achieving One Health: A Rapid Review.

Authors:  Eliudi S Eliakimu; Linda Mans
Journal:  Front Public Health       Date:  2022-01-20

4.  Tuberculosis, HIV/AIDS and Malaria Health Services in sub-Saharan Africa - A Situation Analysis of the Disruptions and Impact of the COVID-19 Pandemic.

Authors:  Pascalina Chanda-Kapata; Francine Ntoumi; Nathan Kapata; Patrick Lungu; Luchenga Adam Mucheleng'anga; Jeremiah Chakaya; John Tembo; Cordelia Himwaze; Rashid Ansumana; Danny Asogun; Sayoki Mfinanga; Peter Nyasulu; Peter Mwaba; Dorothy Yeboah-Manu; Alimuddin Zumla; Jean B Nachega
Journal:  Int J Infect Dis       Date:  2022-03-25       Impact factor: 12.074

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.